Navigation Links
BMP Sunstone Receives Import Drug License (IDL) from SFDA
Date:5/27/2008

at are other than statements of historical facts, including but not limited to the anticipated distribution date of 0.8mm Propess, the anticipated expansion of the Company's distribution network, the anticipated number of patients that will use Propess in the future, the ability of Propess to increase the Compnay's competitiveness, and the anticipated increase in product margins from 0.8mm Propess versus 1.1mm Propess. These statements are subject to uncertainties and risks including, but not limited to, our ability to obtain sufficient quantities of 0.8mm Propess to distribute by September 2008, to successfully market 0.8mm Propess, to bring additional hospitals into our distribution network and to realize additional profit margins on from 0.8mm Propess versus 1.1 mm Propess and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All such forward- looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

BMP Sunstone Corporation

Fred M. Powell

Chief Financial Officer

Tel: +1-610-940-1675

Integrated Corporate Relations, Inc.

Ashley Ammon MacFarlane and Christine Duan

Tel: +1-203-682-8200 (Investor Relations)


'/>"/>
SOURCE BMP Sunstone Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial
2. Nikon Instruments Receives Record Number of Entries for Nikon Small World
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. febit Receives U.S. Patent for Microfluidic Extraction Method
5. Prime Therapeutics Receives VIPPS Accreditation
6. Tasker Products Receives Authorization from USDA for its Tasker Clear for use in Meat and Pork Industries
7. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
8. Albert Einstein College of Medicine Receives $25-Million Gift to Support Stem Cell and Epigenomic Research and Clinical Skills Training
9. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
10. Atrium Medical Receives FDA Approval for its Novel C-QUR Lite(TM) V-Patch and C-QUR Edge(TM) V-Patch
11. Nektar Receives Patent Covering Pulmonary Targeted Antibiotics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... patient has been dosed in its Phase 1 ... and cisplatin for the treatment of malignant pleural ...  Polaris Group is conducting clinical trials on ADI-PEG ... other agents, for the treatment of several other ...
(Date:11/18/2014)... -- Cord Blood Registry® (CBR®) announces that the ... Stem Cell Summit, the largest global meeting of stem cell ... Summit will be held December 3-5 at the Marriott Rivercenter ... The World Stem Cell Summit aims to ... convening the most prominent figures in the field to share ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring ... professor in the Regulatory Biology Laboratory at the Salk Institute, ... to an “off switch” for drug resistance in cancer. , ... research is making a global impact in the fight against ... host Cheryl K. Goodman, CEO of Social Global Mobile LLC, ...
(Date:11/18/2014)... 18, 2014 2014 Deep ... is professional and in-depth report on Polytetrahydrofuran ... information, including its definition, characterization, application, and ... This exploration covers the worldwide business investigation, ... examination covering macroeconomic environment & financial circumstance ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... in Cancer Stem Cell Biology Enhances, MacroGenics, Oncology Capabilities ... ... Platforms, ROCKVILLE, Md., July 17 MacroGenics, Inc., a ... and infectious diseases, today announced the,acquisition of Raven Biotechnologies, Inc., ...
... Arno Therapeutics,Inc. (OTC Bulletin Board: ARNI), today announced ... Board has changed from "LRRI.OB" to "ARNI.OB",effective July ... Therapeutics, Inc. is a clinical-stage biopharmaceutical company,that develops ... patients. Arno,s lead compound is AR-67, a novel, ...
... 17 Following intense,speculation in sections of ... Sankyo,Company, Limited (TSE: 4568.JP) ("Daiichi Sankyo") and ... the agreement,between Daiichi Sankyo, Ranbaxy and the ... is binding and final, subject to,regulatory approvals., ...
Cached Biology Technology:MacroGenics Acquires Raven Biotechnologies 2MacroGenics Acquires Raven Biotechnologies 3Arno Therapeutics Announces New Ticker Symbol 2Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation 2
(Date:11/4/2014)... 5, 2014 – University of Utah engineers developed the ... jet fuel produce electricity without needing to ignite the ... power portable electronics, off-grid power and sensors. , A ... the American Chemical Society journal ACS Catalysis . ... chemical reaction between a fuel and an oxygen-rich source ...
(Date:11/4/2014)... 2014   3D ... Fuel3D , a developer of 3D scanning ... totaling $6.4 million (£4 million). This funding builds on the ... year and paves the way for the commercial launch of ... funding round was led by Chimera Partners and will be ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... CA Researchers from all over the world will be ... Department of Energy Joint Genome Institute 6th Annual Meeting, ... clean energy generation and the environment. Keynote speeches will ... Linear Accelerator Center, and microbial ecologist Terry Hazen of ...
... March 9, 2011 ActiveRx Rehabilitation , a ... working with senior adults, is now available to franchisees ... active aging. ActiveRx Development Company, Inc., based ... qualified operators interested in single or multi-location opportunities and ...
... - Hybrid plants with multiple genome copies show evidence of ... the genes of the other parent, even to the point ... Brian Dilkes, an assistant professor of genetics at Purdue University, ... California Davis and University of Southern California to study the ...
Cached Biology News:New Healthcare Franchise Opportunity Focuses on Treating Exploding Senior Population 2Study shows how plants sort and eliminate genes over millennia 2
Request Info...
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Request Info...
Request Info...
Biology Products: